AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|
13.5 C
New York
Tuesday, October 20, 2026

Tag: kidney function

newssourceFORcompanycontentinformation1releasesmarket

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as...

Helix to Present Three-Year Genomic Screening Outcomes at ASHG 2026 Opening Plenary

Additional studies ranging from GLP-1 to dementia draw on a Helix GenoSphere™ resource that now includes over 620,000 paired EHR + Claims + Genomics records.SAN...

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

STOCKHOLM, Oct. 19, 2026 /PRNewswire/ -- Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society...

XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation

Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage reference molecules targeting the...

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health

MANASSAS, Va., June 13, 2026 /PRNewswire/ -- PureHealth Research today addressed the growing demand for proactive kidney wellness with its collection of science-backed renal...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

Age is just a Number. Mobility is a Choice.

Robotics at Zydus Hospitals, Gujarat are revolutionising Joint Replacement Surgeries in the ElderlyAHMEDABAD, India, June 11, 2026 /PRNewswire/ -- Osteoarthritis and chronic joint degeneration affect...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsKidney function

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers